TISIDB

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type II membrane protein.
Domain	PF01391 Collagen triple helix repeat (20 copies) PF03523 Macrophage scavenger receptor PF00530 Scavenger receptor cysteine-rich domain
Function	Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL) (PubMed:2251254). Isoform III does not internalize acetylated LDL (PubMed:9548586).

> Gene Ontology [ TOP ]
Biological Process	GO:0006869 lipid transport GO:0006898 receptor-mediated endocytosis GO:0010742 macrophage derived foam cell differentiation GO:0010743 regulation of macrophage derived foam cell differentiation GO:0010744 positive regulation of macrophage derived foam cell differentiation GO:0010876 lipid localization GO:0010878 cholesterol storage GO:0010883 regulation of lipid storage GO:0010884 positive regulation of lipid storage GO:0010885 regulation of cholesterol storage GO:0010886 positive regulation of cholesterol storage GO:0015850 organic hydroxy compound transport GO:0015918 sterol transport GO:0019915 lipid storage GO:0030301 cholesterol transport GO:0034381 plasma lipoprotein particle clearance GO:0042953 lipoprotein transport GO:0044872 lipoprotein localization GO:0051235 maintenance of location GO:0071407 cellular response to organic cyclic compound GO:0090077 foam cell differentiation GO:0097006 regulation of plasma lipoprotein particle levels
Molecular Function	GO:0005044 scavenger receptor activity GO:0030169 low-density lipoprotein particle binding GO:0038024 cargo receptor activity GO:0071813 lipoprotein particle binding GO:0071814 protein-lipid complex binding
Cellular Component	GO:0005581 collagen trimer GO:0030139 endocytic vesicle GO:0030659 cytoplasmic vesicle membrane GO:0030666 endocytic vesicle membrane GO:0032994 protein-lipid complex GO:0034358 plasma lipoprotein particle GO:0034362 low-density lipoprotein particle GO:1990777 lipoprotein particle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome
Reactome	R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors R-HSA-3000480: Scavenging by Class A Receptors R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MSR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MSR1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
21383767	Pancreatic Carcinoma	Inhibit immunity	Absence of scavenger receptor A promotes dendritic cell-mediated cross-presentation of cell-associated antigen and antitumor immune response. Selective downregulation or blockade of this immunoregulatory molecule may lead to enhanced potency of DC-based vaccines capable of breaking immune tolerance against cancer.
22896667	Prostate Carcinoma	Inhibit immunity	In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer. SRA/CD204-silenced DCs were highly efficient in generating antigen or tumor-specific T cells with increased effector functions (e.g., cytokine production and tumoricidal activity). SRA/CD204 silencing-enhanced tumor cell death was associated with elevated IFN-γ levels in tumor tissue and increased tumor-infiltrating CD8(+) cells.
17510431	Melanoma	Inhibit immunity; Resistant to immunotherapy	Scavenger receptor-A negatively regulates antitumor immunity. The lack of SR-A significantly enhances HSP- or lipopolysaccharide-mediated vaccine activities against poorly immunogenic tumors, indicating that SR-A is able to attenuate immunostimulatory effects of adjuvants or "danger" molecules. The improved antitumor response in SR-A knockout mice is correlated with an increased antigen-specific T-cell response. Moreover, SR-A-deficient dendritic cells are more responsive to inflammatory stimuli and display a more effective antigen-presenting capability compared with wild-type cells.
21914786	Melanoma	Inhibit immunity	Our studies establish that downregulating SRA/CD204 strongly enhances DC-mediated antitumor immunity. Using SRA/CD204-silenced DCs to generate antigen-targeted vaccines, we documented a marked increase in the level of antitumor immunity achieved against established B16 tumors and metastases.

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MSR1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MSR1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.597	0.274
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.831	0.673
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.418	0.759
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.299	0.506
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.503	0.79
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.04	0.987
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.231	0.667
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.267	0.883
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.19	0.925
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.865	0.583
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.195	0.65
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.037	0.85

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MSR1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	8.2	-0.8	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	5.9	13.1	0.355
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	0	7.9	0.26
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MSR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MSR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MSR1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MSR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MSR1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MSR1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MSR1
Name	macrophage scavenger receptor 1
Aliases	SCARA1; CD204; SR-A; phSR1; phSR2; macrophage acetylated LDL receptor I and II; macrophage scavenger recepto ......
Chromosomal Location	8p22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MSR1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MSR1